Advancing Thyroid Cancer Research:

Key Insights into Clinical Trial Design and Success Factors

INGENŪ CRO

Introduction

Thyroid cancer represents a dynamic and multifaceted area of oncology, with cases increasing worldwide due to advancements in diagnostic techniques and heightened awareness.

Despite the indolent nature of many subtypes, such as papillary thyroid carcinoma, more aggressive forms like anaplastic thyroid cancer pose significant treatment challenges.

This whitepaper delves into the latest insights into thyroid cancer, including epidemiology, genetic underpinnings, therapeutic advancements, and unmet clinical needs. Drawing on a foundation of evidence-based research and clinical expertise, it explores how emerging molecular profiling and targeted therapies are reshaping outcomes for patients across the disease spectrum. By addressing key trends, pivotal endpoints, and innovative treatment strategies, this report serves as a valuable resource for healthcare professionals and stakeholders dedicated to improving thyroid cancer care.

This physician-led exploration highlights our commitment to advancing understanding and fostering innovation in thyroid cancer management, ensuring patients receive precise and personalized interventions.

iNGENŪ CRO

Book a Discovery Call to learn how iNGENū can deliver high-quality, cost-efficient, FDA-compliant research for your next clinical trial

Why Choose iNGENū CRO?

iNGENū is the FDA-centric Australian CRO championing disruptive, innovative biotech firms. We are physician-led, providing access to the full spectrum of clinical and non-clinical research services.

Local Trials, Global Approvals

Australian expertise combined with direct FDA submission capabilities, offering a streamlined path for global approval.

Disciplined, Cost-Efficient Execution

Every dollar is strategically allocated, eliminating unnecessary costs while maintaining the highest quality.

Australian Headquartered, Asia-Pacific Reach

Access high-quality trials in the Asia-Pacific region, enhancing speed and scalability.

Expertise From the Start

Engage directly with our team of highly qualified doctors and PhD scientists from the outset.

Ready to discuss your Clinical Trial?
For further information on how iNGENū can assist you to conduct your clinical trial, book a Discovery Call with one of our Advisors.

Understanding Thyroid Cancer

Overview

Thyroid cancer originates in the thyroid gland, a butterfly-shaped organ located in the front of the neck. It typically presents as a lump or nodule in the thyroid, often discovered during routine physical examinations or imaging studies. While most thyroid nodules are benign, malignancies can arise, leading to varying prognoses depending on the histological subtype.

Key Characteristics

1. Histological Subtypes:

- Papillary Thyroid Carcinoma (PTC): Most common subtype, generally indolent with excellent prognosis.
- Follicular Thyroid Carcinoma (FTC): Second most common, often associated with iodine deficiency.
- Medullary Thyroid Carcinoma (MTC): Linked to genetic mutations like RET; less common but more aggressive.
- Anaplastic Thyroid Carcinoma (ATC): Rare but highly aggressive, with poor survival rates.

2. Prognosis:

- PTC and FTC have high 5-year survival rates (>95% for early-stage cases).
- ATC has a poor prognosis, with less than 10% 5-year survival.

3. Risk Factors:

- Radiation Exposure: Particularly during childhood or from environmental disasters.
- Iodine Deficiency: Linked to a higher risk of FTC in endemic regions.
- Genetic Predispositions: Includes BRAF mutations in PTC and RET mutations in MTC.

4. Clinical Presentation:

- Commonly presents as a painless thyroid nodule or mass.
- Advanced cases may show symptoms like hoarseness, dysphagia, or lymphadenopathy.

5. Treatment Response:

- Differentiated cancers (PTC, FTC) respond well to surgery and radioactive iodine (RAI) therapy.
- Poor response to standard treatments in ATC, requiring alternative or palliative approaches.

Overview

Contributing Factors

Biological Factors:

- Thyroid cancer development is strongly influenced by genetic mutations and alterations. BRAF V600E mutations are commonly found in papillary thyroid carcinoma (PTC), while RAS mutations are associated with follicular thyroid carcinoma (FTC). Familial syndromes like multiple endocrine neoplasia type 2 (MEN2) significantly increase the risk of medullary thyroid carcinoma (MTC). Advances in genetic testing over time have facilitated early detection and improved risk stratification in at-risk populations.

Psychological Factors:

- A diagnosis of thyroid cancer can induce significant psychological stress, often manifesting as anxiety, depression, and concerns about body image following surgery or treatment. These effects can influence treatment adherence and overall quality of life. Over the years, patient support groups, counseling services, and educational resources have played a pivotal role in addressing these challenges and empowering patients to navigate their treatment journey with confidence.

Environmental Factors:

- Exposure to ionizing radiation, especially during childhood or due to environmental disasters, remains a major risk factor for thyroid cancer. Additionally, iodine deficiency has been linked to an increased incidence of FTC in regions where iodine supplementation is inadequate. Public health interventions, such as mandatory iodine fortification in salt, have significantly reduced iodine-deficiency-related thyroid cancer globally, highlighting the impact of preventive measures.

Diagnostic Criteria

ICD-11 code 2D10 pertains to "Malignant neoplasms of the thyroid gland," encompassing various thyroid cancers. The World Health Organization (WHO) provides detailed clinical descriptions and diagnostic requirements for these malignancies in the "Clinical Descriptions and Diagnostic Requirements for ICD-11 Mental, Behavioural and Neurodevelopmental Disorders" (CDDR).

The diagnostic criteria for thyroid malignancies under ICD-11 include:

1. **Histopathological Confirmation:** Diagnosis is established through microscopic examination of thyroid tissue, identifying malignant cellular characteristics specific to thyroid cancer subtypes.

2. **Clinical Presentation:** Patients may exhibit symptoms such as a palpable neck mass, dysphagia (difficulty swallowing), hoarseness, or unexplained weight loss. However, some thyroid cancers are asymptomatic and detected incidentally.

3. **Imaging Studies:** Ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI) may reveal nodules or masses within the thyroid gland suggestive of malignancy.

4. **Laboratory Findings:** Abnormal thyroid function tests or elevated serum calcitonin levels (particularly in medullary thyroid carcinoma) can support the diagnosis.

5. Exclusion of Other Conditions: Differential diagnosis should rule out benign thyroid conditions, such as goiter or benign adenomas, and other neck masses.

Prevalence and Market Analysis

Historical Perspectives & Evolution of Understanding

Thyroid cancer was first recognized in the 19th century, with early treatments limited to high-risk surgical resections. The mid-20th century saw the introduction of radioactive iodine (RAI) therapy, revolutionizing treatment for differentiated thyroid cancers. Advancements in imaging technologies like ultrasound and fine-needle aspiration biopsy (FNAB) improved early detection and diagnostic accuracy in the late 20th century.

The discovery of key genetic mutations, such as BRAF and RET/PTC, has since transformed the understanding of thyroid cancer, paving the way for personalized medicine and targeted therapies like tyrosine kinase inhibitors (TKIs). More recently, efforts to address overdiagnosis have refined risk stratification, focusing on avoiding overtreatment of indolent cases. These advancements have significantly improved prognosis and treatment outcomes over time.

Statistics and Prevalence

- **Prevalence (2023):** Thyroid cancer accounts for 3.4% of all new cancer cases in the United States, with approximately 43,720 new diagnoses and 2,120 deaths annually (American Cancer Society).
- **Trend Analysis:** From 2013 to 2023, thyroid cancer incidence increased annually by 2.4%, largely due to improved diagnostic techniques. However, the mortality rate has remained stable.
- **Future Projections:** Incidence is expected to plateau or slightly decline over the next decade, driven by enhanced risk stratification methods that prevent overdiagnosis.

Market Analysis

The global thyroid cancer treatment market was valued at $2.8 billion in 2022 and is projected to grow at a CAGR of 4.9% through 2030. Factors such as the increasing prevalence of thyroid cancer and advancements in targeted therapies are driving market expansion.

Drug Name	Manufacturer	Market Share (%)	Earning Potential (USD)
Lenvima (lenvatinib)	Eisai	35	$980 million
Nexavar (sorafenib)	Bayer	25	$700 million
Cabometyx (cabozantinib)	Exelixis	20	$560 million
Retevmo (selpercatinib)	Eli Lilly	10	$280 million
Cometriq (cabozantinib)	Exelixis	10	$280 million

Epidemiology of Thyroid Cancer

Global Prevalence

Thyroid cancer is the most common endocrine malignancy globally, with an estimated 586,000 new cases in 2020 according to GLOBOCAN. Incidence rates vary significantly between regions, largely due to differences in diagnostic practices and environmental factors such as iodine intake. High-income countries, including the United States and Japan, report the highest prevalence, partly because of advanced screening and detection technologies. Despite increasing incidence rates over the past decades, largely attributed to overdiagnosis, mortality rates have remained stable or declined due to improved treatment modalities.

Prevalence by Age

Thyroid cancer is most commonly diagnosed in individuals aged 30 to 50 years, with a median age at diagnosis of 51 years. Pediatric thyroid cancer is rare, accounting for less than 2% of all cases, but tends to exhibit more aggressive behavior. Conversely, older adults, particularly those over 65, may present with more advanced disease and worse prognoses, likely due to delayed detection or more aggressive tumor biology. These age-related differences highlight the need for age-specific screening and management strategies.

Prevalence by Gender

Women are disproportionately affected by thyroid cancer, with a female-to-male incidence ratio of approximately 3:1. This disparity is thought to be influenced by hormonal factors, including the potential role of estrogen in tumor development. Interestingly, although men are less frequently diagnosed, they often present with more advanced disease stages and have worse survival rates. These observations underline the importance of ensuring equitable access to early diagnostic tools for both genders.

Prevalence by Race and Ethnicity

The incidence of thyroid cancer varies across racial and ethnic groups. It is highest among Asian and White populations, likely reflecting genetic predispositions and dietary factors such as iodine consumption. Conversely, Black and Hispanic populations tend to have lower incidence rates but experience worse outcomes due to disparities in access to healthcare and timely diagnosis. Addressing these inequities is critical for improving outcomes across diverse populations.

INGENŪ CRO

Key Endpoints for FDA Approval in Thyroid Cancer Clinical Trials:

1. Progression-Free Survival (PFS):

PFS measures the length of time during and after treatment in which the disease does not progress. It is often the primary endpoint in trials for advanced or refractory thyroid cancer.

Importance: PFS is particularly relevant in advanced-stage thyroid cancers (e.g., radioiodine-refractory differentiated thyroid cancer and anaplastic thyroid carcinoma) where prolonging disease control is a key therapeutic goal.

Challenges: PFS relies on accurate and consistent imaging assessments, which may vary across trial sites. Small tumor size or necrosis can lead to difficulties in determining progression.

2. Overall Survival (OS):

OS refers to the duration of survival from the start of treatment to death from any cause. It is considered the gold standard endpoint in oncology trials.

Importance: OS provides a direct measure of a drug's impact on patient survival, particularly in aggressive subtypes like anaplastic thyroid carcinoma.

Challenges: OS requires long-term follow-up, which can delay the availability of results. Additionally, post-progression therapies may confound the interpretation of survival data.

3. Overall Response Rate (ORR):

ORR evaluates the proportion of patients who achieve a predefined reduction in tumor size, typically categorized as partial or complete response based on RECIST (Response Evaluation Criteria in Solid Tumors).

Importance: ORR is often used as a surrogate endpoint in accelerated approval pathways for drugs targeting advanced thyroid cancer.

Challenges: ORR may not capture the durability of responses, especially in tumors that respond initially but develop resistance.

4. Duration of Response (DoR):

DoR assesses how long a therapeutic response lasts in patients who achieved a partial or complete response.

Importance: Demonstrates the sustained efficacy of treatment, particularly for targeted therapies like tyrosine kinase inhibitors (TKIs).

Challenges: Limited data on long-term outcomes for newer agents can make DoR estimates less reliable in early trials.

5. Quality of Life (QoL) Metrics:

Measures the impact of treatment on patients' physical, emotional, and social well-being using validated tools like the EORTC QLQ-C30 or FACT-G.

Importance: QoL endpoints are increasingly valued in regulatory decisions, especially for advanced cases where cure may not be achievable.

Challenges: Subjective variability in patient-reported outcomes requires rigorous standardization and validation of QoL tools.

FDA-Approved Treatments for Thyroid Cancer

Drug Name	Year of Approval	Sponsor	Mechanism of Action	Therapeutic Effects
Lenvima (lenvatinib)	2015	Eisai	VEGFR, FGFR, PDGFR, KIT, RET Inhibitor: Targets multiple receptor tyrosine kinases involved in angiogenesis and tumor cell proliferation.	Reduces tumor vascularization, inhibits tumor growth, and is effective in progressive, radioiodine-refractory differentiated thyroid cancer.
Nexavar (sorafenib)	2013	Bayer	Multikinase Inhibitor: Blocks VEGFR, PDGFR, RAF kinases, and other signaling pathways involved in tumor growth and angiogenesis.	Slows disease progression in radioiodine-refractory differentiated thyroid cancer by disrupting angiogenesis and cancer cell survival mechanisms.
Cabometyx (cabozantinib)	2019	Exelixis	RET, MET, and VEGFR Inhibitor: Inhibits pathways crucial for cancer cell survival, metastasis, and angiogenesis.	Approved for metastatic medullary thyroid carcinoma and radioiodine-refractory thyroid cancers; reduces tumor progression and improves progression-free survival.
Retevmo (selpercatinib)	2020	Eli Lilly	Selective RET Inhibitor: Specifically targets RET gene fusions and mutations, which are common drivers in certain thyroid cancers.	Demonstrates high efficacy in RET fusion-positive thyroid cancers, leading to significant tumor regression and durable response rates.
Cometriq (cabozantinib)	2012	Exelixis	Multikinase Inhibitor: Targets MET, VEGFR, and RET pathways involved in tumorigenesis and cancer spread.	Used for metastatic medullary thyroid carcinoma, effectively inhibits tumor growth and delays disease progression.

Pivotal Clinical Trials for Top Drugs for Thyroid Cancer

Drug Name	NCT Number	Sample Size	Key Findings and Statistical Data
Lenvima (lenvatinib)	NCT01321554	392	Median Progression-Free Survival (PFS) of 18.3 months for lenvatinib vs. 3.6 months for placebo; Hazard Ratio (HR) = 0.21.
Nexavar (sorafenib)	NCT00984282	417	Significant improvement in PFS: 10.8 months for sorafenib vs. 5.8 months for placebo.
Cabometyx (cabozantinib)	NCT03690388	187	Response rate of 34% in RET-positive cases.
Retevmo (selpercatinib)	NCT03157128	143	Overall Response Rate (ORR) of 69% in RET fusion-positive thyroid cancers.
Cometriq (cabozantinib)	NCT00704730	330	Improved PFS: 11.2 months for cabozantinib vs. 4.0 months for placebo.

Approved Product Analysis: Lenvima (lenvatinib)

14.1 Differentiated Thyroid Cancer

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Adults with locally recurrent or metastatic radioactive iodine-refractory differentiated thyroid cancer	Progression-Free Survival (PFS)	RECIST 1.1, Kaplan-Meier analysis	Median: 18.3 months (LEN), 3.6 months (placebo)	N=392 (LEN: 261, Placebo: 131)	Lenvatinib showed a significant improvement in median PFS: 18.3 months vs. 3.6 months (HR: 0.21, 95% CI: 0.16-0.28, p<0.001).
	Objective Response Rate (ORR)	RECIST 1.1	NA	N=392 (LEN: 261, Placebo: 131)	Lenvatinib: 65% (59%-71%), Placebo: 2% (0%-4%). Complete response in LEN: 2%; Placebo: 0%. Partial response in LEN: 63%; Placebo: 2% (p<0.001).
	Overall Survival (OS)	Kaplan-Meier analysis	Not Estimable	N=392 (LEN: 261, Placebo: 131)	OS was not statistically different between groups. Median OS not estimable in either group (HR: 0.73, 95% CI: 0.50-1.07, p=0.10).

Study Design: Multicenter, randomized (2:1), double-blind, placebo-controlled trial.

Population Details:
- Median age: 63 years.
- 40% were aged ≥65 years.
- 79% were White; 51% were male.
- Metastases: lungs (89%), lymph nodes (52%), bone (39%), liver (18%), brain (4%).

1. **Randomization**: Stratified by geographic region, prior VEGF/VEGFR-targeted therapy, and age group (≤65 years vs >65 years).
2. **Statistical Significance**:
   - PFS: p<0.001.
   - ORR: p<0.001.
   - OS: p=0.10 (not significant).
3. **Crossover**: 83% of placebo patients crossed over to open-label lenvatinib upon progression.

Approved Product Analysis: Cabometyx (cabozantinib)

14.2 Hepatocellular Carcinoma

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Adults with Hepatocellular Carcinoma (HCC) who had previously received sorafenib and had Child-Pugh Class A liver impairment	Overall Survival (OS)	Kaplan-Meier curve; Cox proportional-hazard model	Median follow-up: ~36 months (as per KM curves)	N=707 (470 CABOMETYX, 237 Placebo)	Median OS: 10.2 months (CABOMETYX) vs. 8.0 months (Placebo); HR=0.76 (95% CI: 0.63, 0.92); p=0.0049.
Adults with Hepatocellular Carcinoma (HCC)	Progression-Free Survival (PFS)	Kaplan-Meier curve; Cox proportional-hazard model	Median follow-up: ~36 months (as per KM curves)	N=707 (470 CABOMETYX, 237 Placebo)	Median PFS: 5.2 months (CABOMETYX) vs. 1.9 months (Placebo); HR=0.44 (95% CI: 0.36, 0.52); p<0.0001.
Adults with Hepatocellular Carcinoma (HCC)	Objective Response Rate (ORR)	Partial responses (RECIST 1.1 criteria)	Not specified explicitly	N=707 (470 CABOMETYX, 237 Placebo)	Confirmed ORR: 4% (CABOMETYX) vs. 0.4% (Placebo); p=0.0086.

Additional Observations:

1. **Study Design:**
   - Randomized (2:1), double-blind, placebo-controlled, multicenter trial (NCT01908426).
   - Stratification factors: etiology (HBV/HCV/other), geographic region (Asia vs. other regions), and macrovascular invasion (Yes/No).
2. **Patient Characteristics:**
   - Median age: 64 years (range: 22–86 years).
   - Gender: 82% male.
   - Race/Ethnicity: 56% White, 34% Asian.
   - ECOG Performance Status: 0 (53%) or 1 (47%).
   - Disease etiology: HBV (38%), HCV (21%), other causes (40%).
   - 78% had macroscopic vascular invasion or extrahepatic tumor spread; 41% had AFP ≥400 mcg/L.
3. **Statistical Methods:**
   - Significance level set at 0.021 for OS due to O'Brien-Fleming method.
   - PFS and ORR also showed statistically significant differences between CABOMETYX and Placebo groups.

Approved Product Analysis: Retevmo (selpercatinib)

14.2 RET-Mutant Medullary Thyroid Cancer

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
RET-Mutant MTC previously treated with cabozantinib or vandetanib	Overall Response Rate (ORR)	Confirmed ORR assessed by BIRC	Not specified	N=55	ORR: 69% (95% CI: 55%, 81%), with 9% complete response and 60% partial response.
RET-Mutant MTC previously treated with cabozantinib or vandetanib	Duration of Response (DoR)	Observed duration of response	Not specified	N=55	Median DoR: NE (19.1 months, NE); 76% of patients had a DoR of ≥6 months.
RET-Mutant MTC, cabozantinib and vandetanib-naïve	Overall Response Rate (ORR)	Confirmed ORR assessed by BIRC	Not specified	N=88	ORR: 73% (95% CI: 62%, 82%), with 11% complete response and 61% partial response.
RET-Mutant MTC, cabozantinib and vandetanib-naïve	Duration of Response (DoR)	Observed duration of response	Not specified	N=88	Median DoR: 22.0 months (NE, NE); 61% of patients had a DoR of ≥6 months.

Additional Observations:

1. **Study Design**:
   - Multicenter, open-label, multi-cohort trial (NCT03157128).
   - RET-mutation detection: Majority via NGS (tumor samples: 78% treated, 77.3% naïve; blood/plasma: 4–4.5%), PCR (16–18.2%), or unknown (2–4.5%).
2. **Patient Characteristics**:
   - **Previously treated cohort**:
     - Median age: 57 years (range: 17–84 years).
     - Gender: 66% male.
     - Race/Ethnicity: 89% White, 7% Hispanic/Latino, 1.8% Black.
     - ECOG Performance Status: 0–1 (95%), 2 (5%).
     - Disease status: 98% metastatic; median 2 prior therapies (range: 1–8).
   - **Naïve cohort**:
     - Median age: 58 years (range: 15–82 years); 2.3% aged 12–16.
     - Gender: 66% male.
     - Race/Ethnicity: 86% White, 4.5% Asian, 2.3% Hispanic/Latino.
     - ECOG Performance Status: 0–1 (97%), 2 (3.4%).
     - Disease status: 100% metastatic; prior therapies (18%): kinase inhibitors (8%), chemotherapy (4.5%), anti-PD1/PD-L1 therapy (2.3%), radioactive iodine (1.1%).
3. **Mutation Analysis**:
   - Most common mutation: M918T (82 patients; 33 treated, 49 naïve).
   - Other mutations: extracellular cysteine mutations (27 total), V804M or V804L (11 total), and others (23 total).

Approved Product Analysis: Cometriq (cabozantinib)

COMETRIQ Trial – Metastatic Medullary Thyroid Carcinoma (MTC)

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Adults with metastatic MTC, progressive disease confirmed within 14 months	Progression-Free Survival (PFS)	IRRC-confirmed events using modified RECIST criteria	Median follow-up: 22 months	N=330 (219 COMETRIQ, 111 Placebo)	Median PFS: 11.2 months (COMETRIQ) vs. 4.0 months (Placebo); HR=0.28 (95% CI: 0.19, 0.40); p<0.0001.
Adults with metastatic MTC, progressive disease confirmed within 14 months	Objective Response Rate (ORR)	IRRC-confirmed events using modified RECIST criteria	Not specified	N=330 (219 COMETRIQ, 111 Placebo)	Partial response: 27% (COMETRIQ) vs. 0% (Placebo); p<0.0001. Median duration of response: 14.7 months (95% CI: 11.1, 19.3).
Adults with metastatic MTC, progressive disease confirmed within 14 months	Overall Survival (OS)	Not specified	Planned interim analysis	N=330 (219 COMETRIQ, 111 Placebo)	No statistically significant difference between COMETRIQ and placebo groups.

Additional Observations:

1. **Study Design:**
   - International, multicenter, randomized (2:1), double-blind, placebo-controlled trial.
   - Stratification factors: age (≤65 years vs. >65 years) and prior tyrosine kinase inhibitor (TKI) use (Yes/No).
   - No cross-over allowed.

2. **Patient Characteristics:**
   - Median age: 55 years; 23% were ≥65 years old.
   - Gender: 67% male.
   - Race/Ethnicity: 89% White.
   - ECOG Performance Status: 0 (54%), 1 (36%).
   - Disease characteristics: 92% had undergone thyroidectomy; 48% were RET mutation positive; 25% had two or more prior therapies; 21% were previously treated with a TKI.

3. **Efficacy Highlights:**
   - PFS: Significant improvement observed with COMETRIQ compared to placebo.
   - ORR: Partial responses observed only in the COMETRIQ arm.
   - OS: No significant difference observed between treatment groups.

Analysis of Failed Thyroid Cancer Drug Candidates

Name of Drug	Clinical Trial Identifier	Reason for Termination / Drug Failure	Trend Analysis
Vandetanib	NCT01876784	Lack of efficacy in advanced PTC: Despite promising preclinical data, vandetanib showed limited clinical benefit in patients with progressive papillary thyroid carcinoma (PTC). Tumor responses were inconsistent, and progression-free survival (PFS) gains were not statistically significant compared to placebo.	Focus on targeted therapies: The failure highlighted the importance of refining patient selection criteria, particularly identifying subpopulations most likely to benefit based on genetic or molecular profiles. There is now a shift toward biomarker-driven trials.
Donafenib	NCT02960182	Toxicity concerns: Donafenib, a derivative of sorafenib, showed a concerning toxicity profile, including high rates of severe adverse events like hepatotoxicity and hypertension. These outweighed its potential therapeutic benefits, leading to early trial termination.	Emphasis on safety profiles: This failure underscored the need for next-generation TKIs with improved safety profiles. Current trends favor agents with more selective kinase inhibition to minimize off-target effects.
PLX8394	NCT02428712	Limited activity in non-BRAF cases: Designed to selectively inhibit mutant BRAF, PLX8394 showed limited efficacy in thyroid cancers without the BRAF V600E mutation. Even in BRAF-positive tumors, the responses were not durable.	Mutation-specific drug development: The failure has pushed researchers to conduct more robust preclinical studies to stratify patients by mutation status. There is growing emphasis on combination therapies to overcome resistance and achieve sustained responses.

Unique Failure Points in Thyroid Cancer Clinical Trials

1. Mutation Heterogeneity

Case Example : In a trial for lenvatinib, some patients with thyroid cancer lacking specific targetable mutations (e.g., BRAF V600E or RET rearrangements) showed minimal or no response to treatment, despite promising outcomes in mutation-positive subgroups. This highlights the challenge of treating heterogeneous tumors with single-agent therapies.

Solution: Conduct comprehensive molecular profiling for all trial participants before enrollment to identify actionable mutations. Integrate combination therapies that target multiple pathways to address the diverse genetic landscape of thyroid cancers.

2. Radiological Bias

Case Example : A study evaluating cabozantinib revealed discrepancies in tumor response assessments across trial sites, largely due to variability in radiological imaging interpretations, particularly when measuring small or necrotic lesions. This led to inconsistencies in progression-free survival (PFS) endpoints.

Solution: Implement centralized radiological review processes, using standardized criteria such as RECIST (Response Evaluation Criteria in Solid Tumors) guidelines. Incorporate artificial intelligence (AI)-based tools to improve imaging consistency and accuracy.

3. Late Recruitment

Case Example : Phase III trial investigating a novel TKI for advanced thyroid cancer faced challenges recruiting patients with progressive, late-stage disease, as these patients often had poor performance status or were unwilling to participate in trials due to limited treatment options.

Solution: Increase patient engagement through advocacy groups and targeted outreach programs. Offer incentives such as covering travel costs and providing flexible trial locations. Establish early communication with referring oncologists to encourage timely recruitment.

Safety Concerns

The treatment of thyroid cancer, particularly advanced cases, presents several safety challenges, largely due to the adverse effects of targeted therapies and other interventions. Tyrosine kinase inhibitors (TKIs) such as lenvatinib and sorafenib, while effective in controlling disease progression, are associated with significant side effects, including hypertension, diarrhea, fatigue, and hepatotoxicity. These toxicities can be dose-limiting and may necessitate treatment interruptions or modifications, impacting overall efficacy.

Long-term use of radioactive iodine (RAI) therapy, a standard for differentiated thyroid cancers, poses risks of secondary malignancies, particularly in younger patients, and can result in salivary gland damage leading to xerostomia (dry mouth). Patients undergoing external beam radiation therapy for anaplastic thyroid cancer (ATC) may experience local side effects such as skin burns, esophagitis, and soft tissue fibrosis.

Surgical interventions, while curative in many cases, carry procedural risks such as damage to the recurrent laryngeal nerve, resulting in hoarseness or voice changes, and hypoparathyroidism due to inadvertent removal of or damage to the parathyroid glands. Additionally, the psychological impact of thyroid cancer treatment, including anxiety related to lifelong hormone replacement therapy, underscores the need for comprehensive patient support.

Key Safety Considerations for Specific Therapies

1. Tyrosine Kinase Inhibitors (TKIs):
   - Monitor for hypertension, liver function abnormalities, and QT prolongation with regular blood tests and cardiovascular assessments.
2. Radioactive Iodine Therapy (RAI):
   - Limit cumulative doses to reduce the risk of secondary cancers; provide salivary gland protection strategies, such as hydration and sour candies.
3. Surgical Management:
   - Employ nerve monitoring during surgery to minimize the risk of vocal cord paralysis; ensure preoperative localization of parathyroid glands to preserve function.

Standard of Care Treatment Options

The treatment strategy for thyroid cancer depends on the histological subtype and stage of the disease. Surgery is the cornerstone of treatment for most thyroid cancers, particularly differentiated types like papillary (PTC) and follicular thyroid carcinoma (FTC). A total thyroidectomy is often performed, followed by radioactive iodine (RAI) ablation to eradicate residual thyroid tissue and micrometastases. For smaller, low-risk tumors, lobectomy may suffice, reducing the need for lifelong hormone replacement therapy.

Advanced or refractory thyroid cancers, including medullary thyroid carcinoma (MTC) and anaplastic thyroid carcinoma (ATC), require multimodal approaches. Targeted therapies, such as TKIs (e.g., lenvatinib, cabozantinib), have become the standard for cases unresponsive to RAI, offering significant improvements in progression-free survival. External beam radiation therapy (EBRT) and chemotherapy are often utilized for aggressive subtypes like ATC, but their efficacy is limited, emphasizing the need for novel treatments.

For all patients undergoing thyroidectomy, lifelong thyroid hormone replacement therapy (levothyroxine) is necessary to maintain metabolic homeostasis. Additionally, high-risk patients may benefit from TSH suppression therapy using levothyroxine to reduce the risk of cancer recurrence.

Emerging Standards in Care

1. **Minimally Invasive Techniques:**
   - Advances in robotic-assisted thyroidectomy and endoscopic procedures have reduced recovery times and surgical complications.
2. **Molecular Profiling:**
   - The use of genetic testing to tailor treatment plans is becoming a cornerstone of care for advanced and aggressive cancers.
3. **Supportive Care:**
   - Comprehensive patient management, including nutritional support, mental health services, and survivorship programs, is increasingly recognized as an integral part of thyroid cancer care.

INGENŪ CRO

Strategies to Improve Clinical Trial Protocols for FDA Approval

Improving clinical trial protocols for Idiopathic Hypersomnia is pivotal to advancing our understanding and treatment. The goal is not only to discover new therapeutic strategies but also to ensure these interventions meet the high safety and efficacy standards required.

1. Biomarker-Driven Inclusion Criteria:

Incorporate molecular profiling into trial designs to select patients most likely to benefit from treatment. For instance, focusing on patients with BRAF V600E mutations or RET rearrangements improves the likelihood of showing efficacy in targeted therapies.

2. Adaptive Trial Designs:

Use adaptive designs to allow mid-trial modifications based on interim results, such as expanding cohorts for subgroups showing higher responses or refining dosing strategies.

3. Standardized Imaging and Centralized Review:

Employ RECIST criteria for tumor response evaluations and use independent central imaging reviews to minimize inter-site variability and enhance consistency.

4. Interim Analyses:

Conduct interim analyses for PFS and ORR endpoints to enable accelerated approval pathways, with follow-up studies to confirm long-term OS benefits.

5. Comprehensive Safety Data Collection:

Ensure robust monitoring of adverse events (AEs) and quality of life (QoL) metrics to demonstrate a favorable risk-benefit profile for the drug.

6. Early FDA Engagement:

Engage with the FDA early in the trial design process through pre-IND (Investigational New Drug) meetings or Breakthrough Therapy Designation requests to align study protocols with regulatory expectations.

Notable Key Opinion Leaders in Thyroid Cancer Research

Name	Specialty	Designation	Location	Brief Bio
Bruce G Robinson (MBBS, MD, FRACP)	Oncology; Endocrinology, Diabetes and Metabolism	Endocrinologist, St. Vincent's Private Hospital	New South Wales, Australia	Professor Bruce G. Robinson is a distinguished endocrinologist with extensive experience in thyroid disorders, including thyroid cancer. He has held significant leadership roles in medical research and education, contributing to advancements in endocrine health.
Benjamin J Solomon (MBBS, FRACP, PhD)	Medical Oncology	Professor, Peter MacCallum Cancer Centre	Victoria, Australia	Professor Benjamin J. Solomon is a leading medical oncologist specializing in thoracic malignancies and targeted therapies. He has been instrumental in clinical trials and research focused on improving treatments for various cancers, including thyroid cancer.
Christos S Karapetis (MBBS, FRACP)	Medical Oncology	Professor, Flinders University	South Australia, Australia	Professor Christos S. Karapetis is renowned for his expertise in gastrointestinal cancers and personalized cancer therapy. His research has significantly impacted the management of various cancers, including thyroid malignancies.
Michael J Millward (MBBS, FRACP, PhD)	Medical Oncology	Professor, University of Western Australia	Western Australia, Australia	Professor Michael J. Millward is a leading figure in medical oncology, with a focus on clinical trials and translational research. His work encompasses various cancers, including thyroid cancer, aiming to develop innovative treatment strategies.
Duncan J Topliss (MBBS, FRACP)	Endocrinology, Diabetes and Metabolism	Professor, Monash University	Victoria, Australia	Professor Duncan J. Topliss is an esteemed endocrinologist with a special interest in thyroid diseases, including thyroid cancer. He has contributed extensively to clinical guidelines and research in endocrinology.

References

- Basu, S., & Alavi, A. (2008). Unparalleled contribution of ^18F-FDG PET to medicine over 3 decades. Journal of Nuclear Medicine, 49(1), 17N–21N.
- Cives, M., & Strosberg, J. (2017). Radionuclide therapy for neuroendocrine tumors. Current Oncology Reports, 19(2), 9.
- Dash, A., Chakraborty, S., Pillai, M. R. A., & Knapp, F. F. (2015). Peptide receptor radionuclide therapy: An overview. Cancer Biotherapy and Radiopharmaceuticals, 30(2), 47–71.
- Kim, S. Y., Kim, S.-M., Chang, H., Chang, H.-S., Park, C. S., & Lee, Y. S. (2020). Synergistic anticancer activity of sorafenib, paclitaxel, and radiation therapy on anaplastic thyroid cancer in vitro and in vivo. Head & Neck, 42(12), 3678–3684. PUBMED
- Kjaer, A., & Knigge, U. (2015). Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors. Scandinavian Journal of Gastroenterology, 50(6), 740–747.
- Luster, M., Clarke, S. E., Dietlein, M., Lassmann, M., Lind, P., Oyen, W. J. G., Tennvall, J., & Bombardieri, E. (2008). Guidelines for radioiodine therapy of differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 35(10), 1941–1959.
- Silberstein, E. B., Alavi, A., Balon, H. R., Clarke, S. E. M., Divgi, C., Gelfand, M. J., Goldsmith, S. J., Jadvar, H., Marcus, C. S., Martin, W. H., Royal, H. D., & Stabin, M. G. (2012). The SNMMI practice guideline for therapy of thyroid disease with ^131I 3.0. Journal of Nuclear Medicine, 53(10), 1633–1651.
- Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P., Kulke, M. H., Jacene, H., Bushnell, D., O'Dorisio, T. M., Baum, R. P., Kulkarni, H., Caplin, M. E., Lebtahi, R., Hobday, T., Delpassand, E., Van Cutsem, E., … Kwekkeboom, D. J. (2017). Phase 3 trial of ^177Lu-Dotatate for midgut neuroendocrine tumors. New England Journal of Medicine, 376(2), 125–135.
- Verrienti, A., Grani, G., Sponziello, M., Pecce, V., Damante, G., Durante, C., Russo, D., & Filetti, S. (2022). Precision oncology for RET-related tumors. Frontiers in Oncology, 12, 100.
- Yun, H. J., Kim, H. J., Kim, J., Kim, S. Y., Chang, H. S., Park, C. S., Chang, H. J., & Park, K. C. (2021). Synergistic anticancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide, sorafenib, and radiation therapy in patient-derived anaplastic thyroid cancer models. International Journal of Molecular Sciences, 22(2), 536.

iNGENū CRO

The Australian CRO championing innovative biotech firms for global success.
Delivering high-quality, FDA-compliant clinical research.

If you would like further information on how iNGENū CRO can assist you to conduct your clinical trial, please contact Dr Sud Agarwal or Adam Moodie:

Dr Sud Agarwal
Chief Executive Officer
BSc (Hons), MB ChB FANZCA DDU
dr.sudhanshu@ingenucro.com

Adam Moodie
Director, Scientific Engagement
BSc
adam.moodie@ingenucro.com

Unit 22, 456 St Kilda Road, Melbourne, 3004

www.ingenuCRO.com